2024-07-042024-07-042023-12-15RODRIGUES, Emily Saboia Moura; MORAES, Wildson de Jesus Lima. Evolução dos sintomas residuais e sua relação com comorbidades em pacientes com síndrome pós-covid-19. Orientadora: Rosana Maria Feio Libonati. 2023. 75 f. Trabalho de Curso (Bacharelado em Medicina) - Faculdade de Medicina, Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, 2023. Disponível em: https://bdm.ufpa.br/jspui/handle/prefix/7022. Acesso em: .https://bdm.ufpa.br/jspui/handle/prefix/7022Introduction: Survivors of the COVID-19 pandemic must deal with disabling symptoms that affect the most diverse organ systems and that persist for more than 3 months after the acute phase of the infection. These manifestations were called post-COVID syndrome by the World Health Organization. Objective: This study aimed to evaluate the influence of metabolic comorbidities on the intensity of persistent symptoms reported by patients and the evolution of these complaints over time. Methods: This is an analytical longitudinal study, with 100 individuals who presented persistent residual symptoms after at least 3 months of the acute phase of COVID from april 2022 to april 2023. The intensity of symptoms was assessed in 2 medical appointments, with an interval of at least 6 months and a maximum of 12 months, in which previous comorbidities, anthropometric parameters and laboratory tests were also investigated. Results: 76% of participants were women and the overall average age was 54.3 years. The majority of patients had a mild acute infection (53%), did not experience reinfection (65%), had already received 3 doses of vaccine in the first consultation (51%). The most prevalent symptoms were neuropsychiatric, musculoskeletal and hair loss. The most prevalent metabolic comorbidities were hypertension, obesity and dyslipidemia. There was significant improvement (p<0.001) for all 28 symptoms evaluated, using the Wilcoxon test. There was a considerable increase in pre-diabetes and dyslipidemics after COVID infection. There was no association between the outcome of residual symptoms and metabolic comorbidities, using the Chi-Square and Fisher's Exact tests (p > 0.05). There was no association between the variables reinfection, vaccination and time after acute infection with the evolution of residual symptoms. Conclusion: The intensity of residual symptoms decreased over 12 months. There has been a significant increase in the prevalence of prediabetes and dyslipidemia following COVID infection. Metabolic comorbidities, in isolation, did not influence the outcome of each symptom.Acesso AbertoCOVID longaComorbidadesFatores de riscoAlterações metabólicasLong COVIDComorbiditiesRisk factorsMetabolic changesCNPQ::CIENCIAS DA SAUDE::MEDICINATrabalho de Curso - Graduação - Monografia